Clinical trials
Patient Safety clinical trials
Below are recruiting patient safety clinical trials, each written for real people, not researchers. We’re tracking 1,317 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03579836RecruitingPhase 1/Phase 2
Test BEY1107 plus gemcitabine for pancreatic cancer
This early study tests whether BEY1107 given alone or with gemcitabine can be used safely and may help shrink pancreatic cancer tumors. It mainly looks at safety, side effects, and signs of effectiveness in people with pancreatic ductal cancer.
SeoulAges 20–80 - NCT05093907RecruitingPhase 1/Phase 2
Testing a new cancer drug plus capecitabine for metastatic colon cancer
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
Seoul, Jongro-goAges 19 years+ - NCT05769660RecruitingPhase 1
Study BEY1107 plus temozolomide for recurrent glioblastoma
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
SeoulAges 19 years+ - NCT07323173RecruitingPhase 1
Safety study of LBL-047 in healthy adults and lupus patients
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
Bengbu, AnhuiAges 18–60 - NCT07310134RecruitingPhase 1
Study of ZX-8177 for advanced solid tumors
This trial tests a new oral drug (ZX-8177) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with standard options. The goal is to see if it is safe and helps control the disease.
ShanghaiAges 18 years+ - NCT06874036Recruiting
Bowel prep and colonoscopy safety in heart, kidney, or liver disease
This study tests how well people with chronic heart, kidney, or liver disease tolerate bowel preparation and colonoscopy. It aims to ensure the procedure is safe and effective for you.
Hyderabad, TelanganaAges 18–75 - NCT06792682RecruitingPhase 1
Cord blood cells for poor graft function after transplant
This study tests whether umbilical cord blood cells can help patients whose blood counts have dropped again after a stem cell transplant. It may be an option for people who have recovered initially but later develop low blood cell levels.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07289763RecruitingPhase 2
Study of SHR-2173 for primary membranous nephropathy
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
Nanjing, JiangsuAges 18–75 - NCT07269470RecruitingPhase 2
Dasatinib plus ropeginterferon for new CML
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
Houston, TexasAges 18 years+ - NCT07235280RecruitingEarly Phase 1
Testing dapagliflozin before surgery for early stage lung cancer
This trial tests the safety of dapagliflozin (a diabetes drug) taken before surgery for stage IA lung adenocarcinoma. It may help understand if this drug can slow tumor growth while waiting for surgery.
Los Angeles, CaliforniaAges 22 years+ - NCT07201467RecruitingPhase 1/Phase 2
KN060 for dialysis patients with kidney failure
This study tests an experimental drug called KN060, given to people with end-stage kidney disease on dialysis, to see if it is safe and helps with blood clotting. It may be an option if you are on stable dialysis and not at high risk for bleeding.
Beijing, Beijing MunicipalityAges 18–80 - NCT07185256RecruitingPhase 1/Phase 2
Gene therapy for Best disease retinal trial
This trial tests a gene therapy called OPGx-BEST1 injected under the retina to treat vision loss from Best vitelliform macular dystrophy or a related condition. It may help people with advanced disease who have a specific genetic change in the BEST1 gene.
Los Angeles, CaliforniaAges 18 years+ - NCT06948357RecruitingPhase 2
Eye drops for presbyopia in Chinese adults
This trial tests two eye drops, BRIMOCHOL PF and CARBACHOL PF, to see if they improve near vision in people with presbyopia (age-related difficulty seeing up close). The study is for Chinese adults aged 45-75 who have trouble reading even with glasses or contacts.
Wenzhou, ZhejiangAges 45–75 - NCT05395624RecruitingPhase 1/Phase 2
Safety imaging study of a PET tracer in ALS, Alzheimer, MS, Parkinson
This early-phase study tests the safety of a radioactive tracer (“18F-OP-801”) and how the tracer moves through the body (biodistribution) in people with ALS, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and in healthy volunteers. It also measures how the body processes the tracer (“pharmacokinetics”) to support future studies.
San Francisco, CaliforniaAges 18–80 - NCT06932744RecruitingPhase 3
Testing a new PNH pill for people who haven't had complement therapy
This study tests a new oral medication called MY008211A for people with PNH who have not yet tried complement inhibitors. It aims to improve anemia and reduce the need for blood transfusions by targeting the part of the immune system that destroys red blood cells.
Beijing, Beijing MunicipalityAges 18–75 - NCT07102628RecruitingPhase 3
Early cholesterol treatment after heart attack
This study tests whether giving a new cholesterol-lowering drug, inclisiran, early during a hospital stay after a heart attack can help lower bad cholesterol (LDL) more effectively than usual care. It may reduce the risk of future heart problems.
Capital Federal, Buenos AiresAges 18 years+ - NCT06242379RecruitingPhase 1/Phase 2
Testing stem cell particles for retinitis pigmentosa
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
Bangkok Noi, BangkokAges 18 years+ - NCT07090005Recruiting
Endoscopic weight loss: comparing EndoZip and Apollo ESG
This study compares two different endoscopic procedures (EndoZip and Apollo ESG) to help obese patients lose weight. Both are done through the mouth without cutting the skin, and the goal is to see which works better and is safer.
Los Angeles, CaliforniaAges 21–65 - NCT07078383Recruiting
Study of the Rapidlink device for aorta repair
This trial tests a device called Rapidlink that helps repair blood vessels branching off the aorta during open heart surgery. It may be an option if you need open surgery to fix your thoracic aorta.
Los Angeles, CaliforniaAges 18 years+ - NCT07073040Recruiting
Cold plasma therapy for diabetic foot ulcers with blocked arteries
This trial tests whether adding cold atmospheric plasma (a gentle gas treatment) to a standard procedure that opens blocked leg arteries can help diabetic foot ulcers heal better and faster.
Anshan, LiaoningAges 18–80 - NCT06989892Recruiting
Comparing two dialysis filters for sepsis patients
This trial tests whether a newer, higher-performing dialysis filter helps people with kidney failure and sepsis better than the standard filter. It focuses on patients with high levels of inflammation (measured by a marker called interleukin-6).
Dusit, BangkokAges 18 years+ - NCT07053358RecruitingEarly Phase 1
Gene therapy for wet AMD
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
ShanghaiAges 50 years+ - NCT07017634RecruitingPhase 3
Novosis Putty for spine fusion in lumbar disc disease
This trial tests a new bone graft putty (Novosis Putty) used during a specific type of spine fusion surgery (TLIF) to treat a worn-out disc causing low back and leg pain. The goal is to see if it works as well as or better than current options.
Little Rock, ArkansasAges 21–80 - NCT06997588RecruitingPhase 2
Testing alpelisib for overgrowth syndrome in children and adults
This trial is testing a drug called alpelisib for people with PROS (a rare condition that causes parts of the body to grow too much). The drug targets a specific gene change (PIK3CA mutation) that is often the cause. If you have this condition and it's causing serious symptoms, this study might help shrink or slow the overgrowth, improving your quality of life.
St Louis, MissouriAges 2–100
Hear when a new Patient Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient safety?
- Yes. Clin2 currently lists 1,317 recruiting patient safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.